Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down40.900 -0.450 (-1.088%)

04/11/2021 17:32

Innovent Bio (01801) gets sNDA accepted

[ET Net News Agency, 4 November 2021] Innovent Biologics, Inc. (01801) said the
National Medical Products Administration (NMPA) of China has accepted the supplemental New
Drug Application (sNDA) for sintilimab in combination with chemotherapy (oxaliplatin and
capecitabine) for the first-line treatment of patients with unresectable, locally
advanced, recurrent or metastatic gastric or gastroesophageal junction (G/GEJ)
Sintilimab, marketed as TYVYT (sintilimab injection) in China, is an innovative PD-1
inhibitor with global quality standards jointly developed by the company and Eli Lilly and
Company. (RC)

Remark: Real time quote last updated: 25/01/2022 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2022 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.